With more than two months of financings yet to record for the year, the med-tech industry has already raised more money through IPOs and venture capital rounds than in each of the prior four years. But fewer funds collected through follow-on offerings and private placements puts 2021 about 30% below the full-year total for 2020, which was $59.7 billion.

Mindmaze SA raised $125 million in a debt financing round led by Albacore Capital Group to expand its virtual reality-based digital neurotherapeutics platform. Total funding for Mindmaze now exceeds $235.7 million to date. Investors include the Hinduja Group, Venture Kick, the Foundation for Technological Innovation, and Leonardo DiCaprio. The Mindmaze platform assesses and restores cognitive and motor function in individuals who have sustained neural injuries or impairment from degeneration and aging.

Chinese med-tech firms are still flocking to list on the Hong Kong Stock Exchange despite recent disappointing performances. One of these companies is Shanghai Microport Medbot (Group) Co. Ltd., which is looking to raise up to $1 billion in a Hong Kong initial public offering (IPO). Proceeds from the listing will be used for the R&D and commercialization of its core product Toumai Laparoscopic Surgical Robot.

Isoplexis Corp. has debuted on the Nasdaq, pricing its initial public offering of 8.3 million common shares at $15.00 per share. Shares of the proteomics platform developer (NASDAQ:ISO) were trading slightly under at $13 following the listing. The offering is expected to close on Oct. 12, 2021. The Branford, Conn.-based company is aiming to raise $125 million from the public market to accelerate commercialization of its cell analysis platforms. The single-cell proteomics systems are automated, benchtop products designed to reduce therapeutic development timelines.